Animal models of Alport syndrome.

Author:

Abstract
The last decade of the twentieth century was a very productive period for the study of Alport syndrome. Alport syndrome was shown to result from mutations in certain members of the type IV collagen family of proteins, the α3(IV), α4(IV), and α5(IV) chains. Several hundred different mutations in the COL4A5 gene, which encodes the α5(IV) chain, were described in patients with X‐linked Alport syndrome [1]. A few dozen mutations were found in the COL4A3 and COL4A4 genes, which respectively encode the α3(IV) and α4(IV) chains, in patients with autosomal recessive Alport syndrome [2,3]. Autosomal dominant Alport syndrome, due to heterozygous mutations in COL4A3 or COL4A4, was established as an entity, and distinguished from Fechtner and Epstein syndromes, which arise from mutations in a non‐collagen locus, MYH9 [4–7]. Investigators established that mutations in the α3(IV), α4(IV), or α5(IV) chain typically prevent expression of any of these proteins in glomerular basement membranes (GBM), because these chains must interact with each other in networks in order to be deposited in the GBM [8]. These chains are replaced in the GBM by α1(IV) and α2(IV) chains, which normally disappear, for the most part, from the GBM during the capillary loop stage of glomerular maturation [9–11]. Other extracellular matrix proteins, such as types V and VI collagen and the laminin α2 chain, are aberrantly expressed in the Alport GBM [9,12].